Antibody–drug conjugates in ovarian cancer

Ovarian cancer (OC) management presents a challenging scenario in clinical practice due to its late diagnosis, high recurrence rate, and dismal 5‑year survival rate of 45%—especially in platinum-resistant cases. Antibody–drug conjugates (ADCs) are novel drugs that enable the selective delivery of potent cytotoxic agents directly to tumor cells, thereby maximizing treatment effectiveness while minimizing harm to healthy cells. Recent studies have shown promising results in this regard. Mirvetuximab soravtansine achieved remarkable results in the MIRASOL trial, suggesting it as a potential new standard of care for folate receptor-α-positive platinum-resistant OC treatment. Furthermore, trastuzumab deruxtecan demonstrated promising results in the PanTumor02 trial, showing clinically meaningful efficacy across a broad spectrum of HER2-positive solid tumors. This review article explores the current state of ADCs in ovarian cancer and their potential to improve outcomes in patients with recurrent ovarian cancer, especially in the platinum-resistant setting.